A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan

Internal Medicine

Volumn 53, Issue 21, 2014, Pages 2439-2445

  Kamijo, Yoshito ^a   Takai, Michiko ^a   Fujita, Yuji ^b   Hirose, Yasuo ^c   Iwasaki, Yasumasa ^d   Ishihara, Satoshi ^e   Yokoyama, Takashi ^f   Yagi, Keiichi ^g   Sakamoto, Tetsuya ^h  

^a KITASATO UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c NIIGATA CITY GENERAL HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^e Hyogo Emergency Medical Center   (Japan)

^f Sapporo Higashi Tokushukai Hospital   (Japan)

^g YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^h TEIKYO UNIVERSITY   (Japan)

Author keywords

Methoxetamine; Renal dysfunction; Rhabdomyolysis; Synthetic cannabinoid; Synthetic cathinone

Indexed keywords

AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CATHINONE; CHEMICAL COMPOUND; DEXMEDETOMIDINE; DIAZEPAM; FLUNITRAZEPAM; HALOPERIDOL; MIDAZOLAM; NEUROLEPTIC AGENT; OPIATE; PHENCYCLIDINE; PROPOFOL; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; 2-(3-METHOXYPHENYL)-2-(ETHYLAMINO)CYCLOHEXANONE; ALKALOID; CYCLOHEXANONE DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; DESIGNER DRUG; PSYCHOTROPIC AGENT; STREET DRUG;

ADULT; AGITATION; ARTICLE; CONVULSION; FEMALE; FOOD INTAKE; GLASGOW COMA SCALE; HUMAN; HYPERTENSION; INFUSION; INJURY; INTOXICATION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MENTAL DISEASE; MULTICENTER STUDY; MYDRIASIS; PSYCHOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SUICIDE ATTEMPT; TACHYCARDIA; TRAFFIC ACCIDENT; TREATMENT OUTCOME; URINALYSIS; AGED; CHILD; CLINICAL TRIAL; COMPLICATION; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; INFANT; INFORMATION PROCESSING; JAPAN; MIDDLE AGED; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADULT; AGED; ALKALOIDS; CANNABINOIDS; CHILD; CYCLOHEXANONES; CYCLOHEXYLAMINES; DATA COLLECTION; DESIGNER DRUGS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; JAPAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84908377634     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.2344     Document Type: Article

References (33)

1. Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 40: 296-299, 2011.
2. Vearrier D, Osterhoudt K. A teenager with agitation-higher than she should have climbed. Pediatr Emerg Care 26: 462-464, 2010.
3. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197: 157-162, 2010.
4. Hermanns-Clausen M, Sauer O, Gerber G, et al. New “herbal drugs” of abuse: spice and smoke. Clin Toxicol 47: 452, 2009.
5. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas Poison Centers. J Addict Dis 30: 351-358, 2011.
6. Forrester MB. Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care 28: 985-989, 2012.
7. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Experi Toxicol 31: 1006-1011, 2012.
8. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 60: 435-438, 2012.
9. Westerbergh J, Hulten P. Novel synthetic cannabinoids, CRA 13, JWH-015, JWH-018 and JWH-210 - detected in a case series. Clin Toxicol 49: 222, 2011.
10. Herbert JX, Duggan E, Tracey JA. The effect of legislation on synthetic cannabinoid abuse in Ireland. Clin Toxicol 49: 240, 2011.
11. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/index.html [Accessed 1 September, 2014].
12. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5: 60, 2011.
13. Atwood BK, Huffman J, Straiker A, Makcie K. JWH-018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol 160: 585-593, 2010.
14. Wintermeyer A, Moller I, Thevis M, et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Ann Bioanal Chem 398: 2141-2153, 2010.
15. Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: The emerging ‘incense’ and ‘bath salt’ phenomenon. CCJM 79: 258-264, 2012.
16. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198: 31-38, 2010.
17. Fernandez MC, Roth B, Villarreal CL. Fake marijuana causing real problems in Texas. Clin Toxicol 49: 212-213, 2011.
18. Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129: e1064-e1067, 2012.
19. Corazza O, Assi S, Schifano F. From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 19: 454-460, 2013.
20. Jansen KLR. Near-death experiences and the NMDA receptor. BMJ 298: 1708, 1989.
21. Schields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS. Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation. Clin Toxicol 50: 438-440, 2012.
22. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 68: 853-856, 2012.
23. Wood DM, Dargan PI. Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34: 363-367, 2012.
24. Loeffler G, Craig C. Methoxetamine misuse and toxicity. J Stud Alcohol Drugs 74: 816-817, 2013.
25. Coppola M, Mondola M. 3, 4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology, and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208: 12-15, 2012.
26. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8: 33-42, 2012.
27. Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE. Deaths involving methylenedioxyprovalerone (MDPV) in upper east Tennessee. J Forensic Sci 58: 1558-1562, 2013.
28. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3, 4- methylenedioxypyrovalerone (MDPV). J Med Toxicol 8: 69-75, 2012.
29. Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive “bath salts” intoxication with methylenedioxypyrovalerone. Am J Med 125: 854-858, 2012.
30. Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as “bath salts” - Michigan, November 13, 2010-March 31, 2011. Morb Mortal Wkly Rep 60: 624-627, 2011.
31. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol 49: 499- 505, 2012.
32. Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 132: 1-12, 2013.
33. Wilson MP, Pepper D, Currier GW, Holloman Jr. GH, Feifel D. The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 13: 26-34, 2012.